Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II SOX + nivolumab with BBT-based S-1 dose adjustment in HER2-negative advanced gastric cancer
jRCTs031230127Phase 2Active, not recruiting
- Start
- Aug 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tegafur, oxaliplatin and nivolumab in gastric cancer (GC) and gastroesophageal junction adenocarcinoma. Primary endpoints: Dose-limiting toxicities, Response rate and 1 more. Started Aug 2023; status: active, not recruiting.
02
Drugs
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on jRCTs031230127.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031230127.